Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the Rules of the House of Representatives, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Committee on Oversight and Reform	
Subcommittee:	_
Hearing Date: 06/07/2021	
Hearing Title :	
The SACKLER Act and Other Policies to Promote Accountability for the Sackler Family's Role in the Opioid Epidemic	
Witness Name: James Carroll	
Position/Title: Former Director of ONDCP, Co-Founding Member of DC Consulting	_
Witness Type: O Governmental Non-governmental	
Are you representing yourself or an organization? Self Organization	
If you are representing an organization, please list what entity or entities you are representing:	
FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY Please complete the following fields. If necessary, attach additional sheet(s) to provide more information. Are you a fiduciary—including, but not limited to a director officer, advisor or resident agent. of any	
Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of	
the organization(s) or entities.	
To the best of my knowledge, I do not have a fiduciary relationship with any entity that has a formal interest in the subject of The SACKLER Act. As a member of DC Consulting and as such, I advise different entities in the general area of illicit drug use and some of my positions/clients include:	
DisposeRX - an at-home disposal solution that provides an eco-friendly way to dispose of medications.	
Opioid Clinical Management - a software company that uses algorithms to identify employers and their health care providers to head off addictions before they start.	
Students Against Destructive Decisions - Senior Advisor for one of the country's largest prevention programs.	
JanOne – a pharmaceutical company that is developing an alternate pain treatment.	

subject matter that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.	
To the best of my knowledge, I am not aware of any federal grants or contracts that any of entities I represent having received in the past thirty-six months related to subject matter of this hearing.	
Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.	
To the best of my knowledge, I am not aware of any contracts, grants or payments originating with a foreign government relating to the subject matter of this hearing.	
Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.	
☐ I have attached a written statement of proposed testimony.	
☑ I have attached my curriculum vitae or biography.	
*Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides: (5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof. (B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include— (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing. (C) The disclosure referred to in subdivision (B)(ii) shall include— (i) the amount and source of each Federal grant (or subgrant	

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's

payment or contract related to the subject matter of the hearing originating with a foreign government.

thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any

in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be

made part of the hearing record.

Witness signature

6/7/21

Date

Jim Carroll

Jim Carroll most recently served as the Nation's "Drug Czar" for three years, unanimously confirmed to the position by the United States Senate. He oversaw an annual budget of \$35 billion, successfully coordinating and monitoring the activities of 16 Federal Government agency budgets and funding.

Under his leadership, overdose deaths declined for the first time in 30 years, federal grants supporting public health programs reached their highest levels, and drug interdictions stood at all-time highs.

Prior to ONDCP, Mr. Carroll served as White House Deputy Chief of Staff and General Counsel for the Office of Management and Budget. He previously served as Washington Counsel, Global Director of Compliance for Ford Motor Company. During the Bush Administration, he served as Special Assistant and Associate Counsel to the President, Deputy General Counsel and Acting General Counsel at the U.S. Department of Treasury, and as an attorney at the U.S. Department of Justice.